from2028 Activists Investors Trump Politicians Serenity Citrini Burry Semianalysis Trade Arbitrage Search

Nuvation Bio Inc - US

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

More about this company

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Sector: —

3 tracked filer(s) hold this · 1 opened, 0 added, 0 trimmed in 30-JUN-2026

Aggregate 13FScore 67 — mean of 3 scored holder(s) · buyers (new/add) avg 63. Higher = the smart money in this name has the better track record.

Filer	13FScore	This quarter	Shares	Value	% of their book
Paul Tudor Jones / Tudor	63	New buy	3,500,000	$3,663,275	0.0%
Stanley Druckenmiller / Duquesne	92	Holds (flat)	4,539,800	$25,786	0.5%
David Einhorn / Greenlight	46	Holds (flat)	34,995	$198,772	0.0%

Beyond 13F — activists, insiders, politicians & research

Citrini Research coverage report library →

Report	Date	Stance
#97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami	2025-05-28	LONG

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-08-16.